Consensus expectations for Krystal Biotech’s Q2 2026 earnings include revenue of $122.61 million and earnings of $1.70 per share, with the stock trading at $346.89 relative to an average analyst price target of $376.75.
The primary metric investors are monitoring is the commercial durability and international expansion of VYJUVEK, the firm's breakthrough redosable gene therapy.
Following a strong start to the fiscal year, the market is scrutinizing whether U.S. patient growth can remain durable while newly launched markets in Germany and Japan begin to contribute meaningfully. Strong execution in these territories is considered critical for Krystal to maintain its high-margin, self-funding operational model while advancing its broader genetic medicine pipeline.